The potential use of ECG-based prognostic instruments in clinical trials and cost-effectiveness analyses of new therapies in acute cardiac ischemia

Journal of Electrocardiology

Volumn 33, Issue , 2000, Pages 263-268

  Kent, David M ^a   Langa, Kenneth M ^b   Selker, Harry P ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Acute coronary syndromes; Cost effectiveness; Glycoprotein IIB IIIA inhibitors; Predictive instruments; Risk stratification; Thrombolytic therapy

Indexed keywords

FIBRINOGEN RECEPTOR;

ANTICOAGULATION; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; ECONOMICS; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REPERFUSION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; THROMBOLYTIC THERAPY;

EID: 0034471406     PISSN: 00220736     EISSN: None     Source Type: Journal    
DOI: 10.1054/jelc.2000.20301     Document Type: Article

References (14)

1. Coronary thrombolysis and the new biology
2. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction
3. An effect model for the assessment of drug benefit: Example of antiarrhythmic drugs in postmyocardial infarction patients
4. Health care and the United States economic system: An essay in abnormal physiology
5. Selection of thrombolytic therapy for individual patients: Development of a clinical model
6. Which patients benefit most from early thrombolytic therapy with intracoronary streptokinase?
7. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41, 021 patients
8. Patient-specific predictions of outcomes in myocardial infarction for real time emergency use: A thrombolytic predictive instrument
9. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction
10. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
11. Validating an independently-derived predictive model on the GUSTO trial population
12. Cost effectiveness of thrombolytic therapy with tissue plaminogen activator compared with streptokinase for acute myocardial infarction
13. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes
14. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease